16-8811126-T-C
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_000303.3(PMM2):āc.395T>Cā(p.Ile132Thr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000028 in 1,426,088 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. I132N) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000303.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PMM2 | NM_000303.3 | c.395T>C | p.Ile132Thr | missense_variant | 5/8 | ENST00000268261.9 | NP_000294.1 | |
PMM2 | XM_047434215.1 | c.146T>C | p.Ile49Thr | missense_variant | 3/6 | XP_047290171.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PMM2 | ENST00000268261.9 | c.395T>C | p.Ile132Thr | missense_variant | 5/8 | 1 | NM_000303.3 | ENSP00000268261.4 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000995 AC: 2AN: 201056Hom.: 0 AF XY: 0.00000930 AC XY: 1AN XY: 107496
GnomAD4 exome AF: 0.00000280 AC: 4AN: 1426088Hom.: 0 Cov.: 31 AF XY: 0.00000283 AC XY: 2AN XY: 706112
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
PMM2-congenital disorder of glycosylation Pathogenic:8Other:1
Pathogenic, no assertion criteria provided | clinical testing | Pediatric Metabolic Diseases, Hacettepe University | - | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 20, 2021 | Variant summary: PMM2 c.395T>C (p.Ile132Thr) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 9.9e-06 in 201056 control chromosomes. c.395T>C has been reported in the literature as a compound heterozygous genotype in multiple individuals affected with Congenital Disorder Of Glycosylation Type 1a (example, Matthijs_1998, de Lonlay_2001, Le Bizec_2005, Wu_2018, Quelhas_2021). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no variant specific experimental evidence demonstrating an impact on protein function has been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Nov 03, 2021 | NM_000303.2(PMM2):c.395T>C(I132T) is a missense variant classified as pathogenic in the context of congenital disorder of glycosylation type Ia. I132T has been observed in cases with relevant disease (PMID: 33176815, 19396570, 9497260, 15844218, 32874916, 25355454, 29361989). Functional assessments of this variant are not available in the literature. I132T has been observed in population frequency databases (gnomAD: ASJ 0.01%). In summary, NM_000303.2(PMM2):c.395T>C(I132T) is a missense variant that has been observed more frequently in cases with the relevant disease than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 11, 2023 | For these reasons, this variant has been classified as Pathogenic. This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 132 of the PMM2 protein (p.Ile132Thr). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with PMM2-related disease (PMID: 9497260, 15844218, 25355454, 29361989). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 7718). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PMM2 protein function. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 08, 2024 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Dec 27, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Juno Genomics, Hangzhou Juno Genomics, Inc | - | PM3_VeryStrong+PM2_Supporting+PP3+PP4 - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 01, 2000 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at